The University of California San Francisco Adult Longitudinal Post-Treatment Diffuse Glioma MRI Dataset

Brandon K K Fields,Evan Calabrese,John Mongan,Soonmee Cha,Christopher P Hess,Leo P Sugrue,Susan M Chang,Tracy L Luks,Javier E Villanueva-Meyer,Andreas M Rauschecker,Jeffrey D Rudie

DOI: https://doi.org/10.1148/ryai.230182

Abstract:Supplemental material is available for this article.

What problem does this paper attempt to address?

The University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) Dataset

Evan Calabrese,Javier E. Villanueva-Meyer,Jeffrey D. Rudie,Andreas M. Rauschecker,Ujjwal Baid,Spyridon Bakas,Soonmee Cha,John T. Mongan,Christopher P. Hess

DOI: https://doi.org/10.1148/ryai.220058

2022-03-16

Abstract:Here we present the University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) dataset. The UCSF-PDGM dataset includes 500 subjects with histopathologically-proven diffuse gliomas who were imaged with a standardized 3 Tesla preoperative brain tumor MRI protocol featuring predominantly 3D imaging, as well as advanced diffusion and perfusion imaging techniques. The dataset also includes isocitrate dehydrogenase (IDH) mutation status for all cases and O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status for World Health Organization (WHO) grade III and IV gliomas. The UCSF-PDGM has been made publicly available in the hopes that researchers around the world will use these data to continue to push the boundaries of AI applications for diffuse gliomas.

Computer Vision and Pattern Recognition,Image and Video Processing
The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) MRI Dataset

Jeffrey D. Rudie,Rachit Saluja,David A. Weiss,Pierre Nedelec,Evan Calabrese,John B. Colby,Benjamin Laguna,John Mongan,Steve Braunstein,Christopher P. Hess,Andreas M. Rauschecker,Leo P. Sugrue,Javier E. Villanueva-Meyer

DOI: https://doi.org/10.1148/ryai.230126

2024-05-31

Abstract:The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) dataset is a public, clinical, multimodal brain MRI dataset consisting of 560 brain MRIs from 412 patients with expert annotations of 5136 brain metastases. Data consists of registered and skull stripped T1 post-contrast, T1 pre-contrast, FLAIR and subtraction (T1 pre-contrast - T1 post-contrast) images and voxelwise segmentations of enhancing brain metastases in NifTI format. The dataset also includes patient demographics, surgical status and primary cancer types. The UCSF-BSMR has been made publicly available in the hopes that researchers will use these data to push the boundaries of AI applications for brain metastases. The dataset is freely available for non-commercial use at <a class="link-external link-https" href="https://imagingdatasets.ucsf.edu/dataset/1" rel="external noopener nofollow">this https URL</a>

Image and Video Processing,Computer Vision and Pattern Recognition
The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation

Yannick Suter,Urspeter Knecht,Waldo Valenzuela,Michelle Notter,Ekkehard Hewer,Philippe Schucht,Roland Wiest,Mauricio Reyes

DOI: https://doi.org/10.1038/s41597-022-01881-7

2022-12-15

Scientific Data

Abstract:Publicly available Glioblastoma (GBM) datasets predominantly include pre-operative Magnetic Resonance Imaging (MRI) or contain few follow-up images for each patient. Access to fully longitudinal datasets is critical to advance the refinement of treatment response assessment. We release a single-center longitudinal GBM MRI dataset with expert ratings of selected follow-up studies according to the response assessment in neuro-oncology criteria (RANO). The expert rating includes details about the rationale of the ratings. For a subset of patients, we provide pathology information regarding methylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) promoter status and isocitrate dehydrogenase 1 (IDH1), as well as the overall survival time. The data includes T1-weighted pre- and post-contrast, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) MRI. Segmentations from state-of-the-art automated segmentation tools, as well as radiomic features, complement the data. Possible applications of this dataset are radiomics research, the development and validation of automated segmentation methods, and studies on response assessment. This collection includes MRI data of 91 GBM patients with a total of 638 study dates and 2487 images.

multidisciplinary sciences
The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics

Spyridon Bakas,Chiharu Sako,Hamed Akbari,Michel Bilello,Aristeidis Sotiras,Gaurav Shukla,Jeffrey D. Rudie,Natali Flores Santamaría,Anahita Fathi Kazerooni,Sarthak Pati,Saima Rathore,Elizabeth Mamourian,Sung Min Ha,William Parker,Jimit Doshi,Ujjwal Baid,Mark Bergman,Zev A. Binder,Ragini Verma,Robert A. Lustig,Arati S. Desai,Stephen J. Bagley,Zissimos Mourelatos,Jennifer Morrissette,Christopher D. Watt,Steven Brem,Ronald L. Wolf,Elias R. Melhem,MacLean P. Nasrallah,Suyash Mohan,Donald M. O’Rourke,Christos Davatzikos

DOI: https://doi.org/10.1038/s41597-022-01560-7

2022-07-29

Scientific Data

Abstract:Abstract Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have reported results from either private institutional data or publicly available datasets. However, current public datasets are limited in terms of: a) number of subjects, b) lack of consistent acquisition protocol, c) data quality, or d) accompanying clinical, demographic, and molecular information. Toward alleviating these limitations, we contribute the “University of Pennsylvania Glioblastoma Imaging, Genomics, and Radiomics” (UPenn-GBM) dataset, which describes the currently largest publicly available comprehensive collection of 630 patients diagnosed with de novo glioblastoma. The UPenn-GBM dataset includes (a) advanced multi-parametric magnetic resonance imaging scans acquired during routine clinical practice, at the University of Pennsylvania Health System, (b) accompanying clinical, demographic, and molecular information, (d) perfusion and diffusion derivative volumes, (e) computationally-derived and manually-revised expert annotations of tumor sub-regions, as well as (f) quantitative imaging (also known as radiomic) features corresponding to each of these regions. This collection describes our contribution towards repeatable, reproducible, and comparative quantitative studies leading to new predictive, prognostic, and diagnostic assessments.

multidisciplinary sciences
Supplementary Table from Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array

Jiuyi Li,Xue Yang,Anna Wenger,Yingyu Sun,Zheng Wang,Chuanbao Zhang,Yunqiu Zhang,Boglarka Fekete,Bertil Rydenhag,Asgeir Store Jakola,Tao Jiang,Helena Carén,Xiaolong Fan

DOI: https://doi.org/10.1158/1078-0432.22471197.v1

2023-01-01

Abstract:Supplementary table shows the information of samples invovled in this study and the information of TLDA assays.
Treatment-aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction

Qinghui Liu,Elies Fuster-Garcia,Ivar Thokle Hovden,Donatas Sederevicius,Karoline Skogen,Bradley J MacIntosh,Edvard Grødem,Till Schellhorn,Petter Brandal,Atle Bjørnerud,Kyrre Eeg Emblem

2023-09-14

Abstract:Diffuse gliomas are malignant brain tumors that grow widespread through the brain. The complex interactions between neoplastic cells and normal tissue, as well as the treatment-induced changes often encountered, make glioma tumor growth modeling challenging. In this paper, we present a novel end-to-end network capable of generating future tumor masks and realistic MRIs of how the tumor will look at any future time points for different treatment plans. Our approach is based on cutting-edge diffusion probabilistic models and deep-segmentation neural networks. We included sequential multi-parametric magnetic resonance images (MRI) and treatment information as conditioning inputs to guide the generative diffusion process. This allows for tumor growth estimates at any given time point. We trained the model using real-world postoperative longitudinal MRI data with glioma tumor growth trajectories represented as tumor segmentation maps over time. The model has demonstrated promising performance across a range of tasks, including the generation of high-quality synthetic MRIs with tumor masks, time-series tumor segmentations, and uncertainty estimates. Combined with the treatment-aware generated MRIs, the tumor growth predictions with uncertainty estimates can provide useful information for clinical decision-making.

Image and Video Processing,Computer Vision and Pattern Recognition
Nimg-75. Similarity Distances-Based Delta Radiomics (Sddr) Enables Longitudinal Mri Comparisons For Survival Prediction In Gliomas: A Multi-Institutional Validation

Gustavo Pineda,Michael Veronesi,Timothy J Stuhlmiller,Hope Lee,Sarah Ginn,Alaa Awawda,Zachariah Cole,Ankush Bhatia,Santosh Kesari,Manmeet Ahluwalia,Eduardo Romero,Marwa Ismail,Pallavi Tiwari

DOI: https://doi.org/10.1093/neuonc/noae165.0839

2024-11-29

Neuro-Oncology

Abstract:Radiomics (computerized feature analysis) on treatment-naive MRI scans has demonstrated great value in outcome prediction for Glioblastoma (GBM). However, delta radiomics (analysis of radiomic feature variation between different events, e.g., before and after treatment) has not been explored on account of challenges with precise spatial correspondences between pre- and post-operative scans. This work presents a survival prediction model for GBM, Similarity Distances-based delta radiomics (SDDR), based on the hypothesis that similarity distance-measures between radiomic features on pre-, and post-treatment images can accurately capture temporal changes within-and-around the tumor, and provide improved prediction of overall survival, compared to models based on a single timepoint. 150 patients from 2 publicly-available Glioma repositories (University of California San Francisco "UCSF" (n=48), LUMIERE (n=67)) and 2 two proprietary datasets (from xCures (n=13), and Cleveland Clinic (CCF) (n=74)) were obtained. UCSF and LUMIERE cohorts were used as separate hold-out sets, in each of which the remaining collections were used as discovery set. Following pre-processing, tumor segmentation into Edema (ED) and Enhancing tumor (ET) were performed. SDDR was then computed, which is the distance between probability densities functions from 156 gray co-occurrence (GLCM) and 52 gradient-based co-occurrences statistics (COLLAGE) features extracted from pre and-post-treatment MRI. Six statistical distances (e.g., Earth mover distance) normalized by the scanning interval (in weeks) yielded n=2496 SDDR measurements per tumor region (1248/region, 936 delta-GLCM, and 312 delta-COLLAGE). The same set of features were computed from pretreatment MRI (Pre-R) for comparison. Features were fed to LASSO-Cox regression for survival analysis. SDDR for GLCM features extracted from ET outperformed Pre-R, and demonstrated significant differences between high and low risk groups for both hold out tests: UCSF (p=0.0069, HR =2.8, C-index=0.69) and LUMIERE (p=0.0061, HR = 1.9, C-index 0.65). SDDR-based multi-institutional survival analysis demonstrated promise in reliable longitudinal risk-stratification in GBM.

oncology,clinical neurology
Pre- and post-surgery brain tumor multimodal magnetic resonance imaging data optimized for large scale computational modelling

Hannelore Aerts,Nigel Colenbier,Hannes Almgren,Thijs Dhollander,Javier Rasero Daparte,Kenzo Clauw,Amogh Johri,Jil Meier,Jessica Palmer,Michael Schirner,Petra Ritter,Daniele Marinazzo

DOI: https://doi.org/10.1038/s41597-022-01806-4

2022-11-05

Abstract:We present a dataset of magnetic resonance imaging (MRI) data (T1, diffusion, BOLD) acquired in 25 brain tumor patients before the tumor resection surgery, and six months after the surgery, together with the tumor masks, and in 11 controls (recruited among the patients' caregivers). The dataset also contains behavioral and emotional scores obtained with standardized questionnaires. To simulate personalized computational models of the brain, we also provide structural connectivity matrices, necessary to perform whole-brain modelling with tools such as The Virtual Brain. In addition, we provide blood-oxygen-level-dependent imaging time series averaged across regions of interest for comparison with simulation results. An average resting state hemodynamic response function for each region of interest, as well as shape maps for each voxel, are also contributed.
The Rio Hortega University Hospital Glioblastoma dataset: a comprehensive collection of preoperative, early postoperative and recurrence MRI scans (RHUH-GBM)

Santiago Cepeda,Sergio Garcia-Garcia,Ignacio Arrese,Francisco Herrero,Trinidad Escudero,Tomas Zamora,Rosario Sarabia

DOI: https://doi.org/10.1016/j.dib.2023.109617

2023-05-02

Abstract:Glioblastoma, a highly aggressive primary brain tumor, is associated with poor patient outcomes. Although magnetic resonance imaging (MRI) plays a critical role in diagnosing, characterizing, and forecasting glioblastoma progression, public MRI repositories present significant drawbacks, including insufficient postoperative and follow-up studies as well as expert tumor segmentations. To address these issues, we present the "Río Hortega University Hospital Glioblastoma Dataset (RHUH-GBM)," a collection of multiparametric MRI images, volumetric assessments, molecular data, and survival details for glioblastoma patients who underwent total or near-total enhancing tumor resection. The dataset features expert-corrected segmentations of tumor subregions, offering valuable ground truth data for developing algorithms for postoperative and follow-up MRI scans. The public release of the RHUH-GBM dataset significantly contributes to glioblastoma research, enabling the scientific community to study recurrence patterns and develop new diagnostic and prognostic models. This may result in more personalized, effective treatments and ultimately improved patient outcomes.

Quantitative Methods,Computer Vision and Pattern Recognition,Machine Learning,Image and Video Processing
Glioma Monitoring Via Longitudinal Intracranial Cerebrospinal Fluid Cell-Free DNA.

Cecile Riviere-Cazaux,Xiaoxi Dong,Wei Mo,Chao Dai,Cody Nesvick,Katherine M. Andersen,Ignacio Jusue-Torres,Noor Malik,Jian Li Campian,Michael W. Ruff,Joon H. Uhm,Jeanette Eckel-Passow,Terry C. Burns,Timothy J. Kaufmann,Sani Haider Kizilbash,Arthur Warrington,Robert B. Jenkins,Lucas Carlstrom,Amanda Munoz-Casabella

DOI: https://doi.org/10.1101/2024.02.21.24303164

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:IMPORTANCE: Current methods for glioma treatment response assessment are limited. Intracranial cerebrospinal fluid (CSF) may provide a previously untapped source of longitudinal biomarkers, such as cell-free DNA (cfDNA), for disease monitoring. OBJECTIVE: To assess the feasibility of obtaining longitudinal intracranial CSF cfDNA from patients with gliomas during their disease course. DESIGN: This case series was initiated in 2021, with patients followed until last clinical follow-up (death or present time). SETTING: This single-center study was conducted at a large academic medical center. PARTICIPANTS: Adults with gliomas were recruited for longitudinal intracranial CSF collection using 1) Ommaya reservoirs, from which CSF would be sampled on at least two separate occasions, or 2) CSF collection from other clinically indicated CSF access devices, such as ventriculoperitoneal (VP) shunts. INTERVENTIONS: CSF was collected from Ommaya reservoirs in four patients and from an existing VP shunt in one patient. MAIN OUTCOMES AND MEASURES: The study aimed to collect CSF for biobanking and biomarker discovery, with the hypothesis that CSF could serve as a source of longitudinally acquirable biomarkers. RESULTS: Five patients (2 females, 3 males; median: 40 years, range 32-64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4/5 patients) or VP shunt (n=1/5). Three patients had glioblastoma and two had astrocytoma, IDH-mutant, grade 4. In total, thirty-five CSF samples were obtained (median: 3.80 mL; 0.5-5 mL), with 30 (85.7%) yielding sufficient cfDNA for Next-Generation Sequencing (n=28) or Low-Pass Whole Genome sequencing (all samples). Tumor fraction was found to increase with radiographic progression. Changes in variant allelic frequencies (VAFs) may be seen within individual patients after resection and chemoradiation. In two patients, changes in tumor-specific IDH1 VAF correlated with CSF D-2-hydroxyglutarate levels, the oncometabolite of IDH mutant tumors. Copy number burden (CNB) decreased below the limit of quantification during treatment. CONCLUSIONS AND RELEVANCE: Longitudinal CSF cfDNA can feasibly be obtained via CSF access devices in patients with gliomas during their disease course. Ongoing studies will evaluate hypotheses generated in this case series regarding how longitudinal CSF cfDNA could be utilized to sensitively detect changes in disease burden. Trial Registration: [NCT04692324][1] https://clinicaltrials.gov/study/[NCT04692324][1]; [NCT04692337][2] https://clinicaltrials.gov/study/[NCT04692337][2]### Competing Interest StatementXiaoxi Dong, Chao Dai, Wei Mo, Pan Du, and Shidong Jia report employment at Predicine, Inc. Wei Mo, Pan Du, and Shidong Jia also report stock and other ownership interests in Predicine, Inc.### Clinical TrialNCT04692337### Funding StatementCRC was supported by the National Institute of Health T32GM145408. AMC was supported by NIH T32GM00868. TCB, TJK, SHK, and JEP were supported by NINDS R61 NS122096. TCB was supported by the Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor Association, Brains Together for the Cure, Humor to fight the Tumor, and Lucius & Terrie McKelvey. ### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mayo Clinic Institutional Review Board and all participants provided their consent to participate in this study. This study was performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon request to the author. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04692324&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F24%2F2024.02.21.24303164.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04692337&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F24%2F2024.02.21.24303164.atom
BIOS-03. REAL WORLD CLINICAL OUTCOMES OF PATIENTS WITH DIFFUSE MIDLINE GLIOMA IN A LONGITUDINAL OUTCOMES REGISTRY

Timothy Stuhlmiller,Asher Wasserman,Jameson Quinn,Mark Shapiro,Santosh Kesari

DOI: https://doi.org/10.1093/neuonc/noac209.079

2022-11-01

Neuro-Oncology

Abstract:Abstract We utilized the longitudinal clinical outcomes registry XCELSIOR (NCT03793088) to understand real world outcomes and treatment patterns among patients with diffuse midline glioma. A total of 74 patients were identified with a diagnosis of diffuse midline glioma by pathology or imaging (36 pediatric and 38 adult patients). Median age at diagnosis was 20 years. As of 6/1/2022, 45 patients had expired. Median overall survival (mOS) of the entire cohort was 16.2 months. Cox proportional hazard ratio analysis identified age as the only significant covariate for OS (pediatric HR = 1.59, p=0.04). Pediatric patients had a mOS of 12.9 months and adult patients a mOS of 18.9 months from diagnosis. Frequency of primary tumor location in this dataset was brainstem (35%), thalamus (23%), and pons (20%). Pons location was associated with worst survival (mOS 11.4 months, n=15 patients). The most common anti-cancer interventions among all patients were ONC201 (39 patients), temozolomide (37 patients), bevacizumab (23 patients), panobinostat (8 patients), and immune checkpoint inhibitors (3 patients each, pembrolizumab and nivolumab). In this dataset, no interventions were statistically significant in a Cox proportional hazard model, but both immune checkpoint inhibitors (HR = -1.24, p=0.11) and ONC201 (HR = -0.38, p=0.27) trended toward benefit in the entire population. The subpopulation of patients treated with ONC201 whose tumor also harbored a TP53 mutation displayed a tendency toward activity (n=8); TP53-mutant patients treated with ONC201 had a mOS of 25.0 months vs. TP53 wild-type patients treated with ONC201 had a mOS of 20.3 months. Annotation of data for additional patients is ongoing and updated analyses will be presented at the meeting.

oncology,clinical neurology
“MASSIVE” brain dataset: Multiple acquisitions for standardization of structural imaging validation and evaluation

Martijn Froeling,Chantal M.W. Tax,Sjoerd B. Vos,Peter R. Luijten,Alexander Leemans

DOI: https://doi.org/10.1002/mrm.26259

2016-05-13

Magnetic Resonance in Medicine

Abstract:PURPOSE: In this work, we present the MASSIVE (Multiple Acquisitions for Standardization of Structural Imaging Validation and Evaluation) brain dataset of a single healthy subject, which is intended to facilitate diffusion MRI (dMRI) modeling and methodology development.METHODS: MRI data of one healthy subject (female, 25 years) were acquired on a clinical 3 Tesla system (Philips Achieva) with an eight-channel head coil. In total, the subject was scanned on 18 different occasions with a total acquisition time of 22.5 h. The dMRI data were acquired with an isotropic resolution of 2.5 mm3 and distributed over five shells with b-values up to 4000 s/mm2 and two Cartesian grids with b-values up to 9000 s/mm2 .RESULTS: The final dataset consists of 8000 dMRI volumes, corresponding B0 field maps and noise maps for subsets of the dMRI scans, and ten three-dimensional FLAIR, T1 -, and T2 -weighted scans. The average signal-to-noise-ratio of the non-diffusion-weighted images was roughly 35.CONCLUSION: This unique set of in vivo MRI data will provide a robust framework to evaluate novel diffusion processing techniques and to reliably compare different approaches for diffusion modeling. The MASSIVE dataset is made publically available (both unprocessed and processed) on www.massive-data.org. Magn Reson Med 77:1797-1809, 2017. © 2016 International Society for Magnetic Resonance in Medicine.

radiology, nuclear medicine & medical imaging
ReMIND: The Brain Resection Multimodal Imaging Database

Parikshit Juvekar,Reuben Dorent,Fryderyk Kögl,Erickson Torio,Colton Barr,Laura Rigolo,Colin Galvin,Nick Jowkar,Anees Kazi,Nazim Haouchine,Harneet Cheema,Nassir Navab,Steve Pieper,William M. Wells,Wenya Linda Bi,Alexandra Golby,Sarah Frisken,Tina Kapur

DOI: https://doi.org/10.1101/2023.09.14.23295596

2024-04-08

Abstract:The standard of care for brain tumors is maximal safe surgical resection. Neuronavigation augments the surgeon’s ability to achieve this but loses validity as surgery progresses due to brain shift. Moreover, gliomas are often indistinguishable from surrounding healthy brain tissue. Intraoperative magnetic resonance imaging (iMRI) and ultrasound (iUS) help visualize the tumor and brain shift. iUS is faster and easier to incorporate into surgical workflows but offers a lower contrast between tumorous and healthy tissues than iMRI. With the success of data-hungry Artificial Intelligence algorithms in medical image analysis, the benefits of sharing well-curated data cannot be overstated. To this end, we provide the largest publicly available MRI and iUS database of surgically treated brain tumors, including gliomas (n=92), metastases (n=11), and others (n=11). This collection contains 369 preoperative MRI series, 320 3D iUS series, 301 iMRI series, and 356 segmentations collected from 114 consecutive patients at a single institution. This database is expected to help brain shift and image analysis research and neurosurgical training in interpreting iUS and iMRI.

Surgery
Data from SlicerDMRI: Open Source Diffusion MRI Software for Brain Cancer Research

Isaiah Norton,Walid Ibn Essayed,Fan Zhang,Sonia Pujol,Alex Yarmarkovich,Alexandra J. Golby,Gordon Kindlmann,Demian Wassermann,Raul San Jose Estepar,Yogesh Rathi,Steve Pieper,Ron Kikinis,Hans J. Johnson,Carl-Fredrik Westin,Lauren J. O'Donnell

DOI: https://doi.org/10.1158/0008-5472.c.6510101

IF: 11.2

2017-01-01

Cancer Research

Abstract:AbstractDiffusion MRI (dMRI) is the only noninvasive method for mapping white matter connections in the brain. We describe SlicerDMRI, a software suite that enables visualization and analysis of dMRI for neuroscientific studies and patient-specific anatomic assessment. SlicerDMRI has been successfully applied in multiple studies of the human brain in health and disease, and here, we especially focus on its cancer research applications. As an extension module of the 3D Slicer medical image computing platform, the SlicerDMRI suite enables dMRI analysis in a clinically relevant multimodal imaging workflow. Core SlicerDMRI functionality includes diffusion tensor estimation, white matter tractography with single and multi-fiber models, and dMRI quantification. SlicerDMRI supports clinical DICOM and research file formats, is open-source and cross-platform, and can be installed as an extension to 3D Slicer (www.slicer.org). More information, videos, tutorials, and sample data are available at dmri.slicer.org. Cancer Res; 77(21); e101–3. ©2017 AACR.
Segmentation of pre- and posttreatment diffuse glioma tissue subregions including resection cavities

Saif Baig,Igor Vidic,George M Mastorakos,Robert X Smith,Nathan White,Suzie Bash,Anders M Dale,Carrie R McDonald,Thomas Beaumont,Tyler M Seibert,Jona Hattangadi-Gluth,Santosh Kesari,Nikdokht Farid,Jeffrey D Rudie

DOI: https://doi.org/10.1093/noajnl/vdae140

2024-08-16

Abstract:Background: Evaluating longitudinal changes in gliomas is a time-intensive process with significant interrater variability. Automated segmentation could reduce interrater variability and increase workflow efficiency for assessment of treatment response. We sought to evaluate whether neural networks would be comparable to expert assessment of pre- and posttreatment diffuse gliomas tissue subregions including resection cavities. Methods: A retrospective cohort of 647 MRIs of patients with diffuse gliomas (average 55.1 years; 29%/36%/34% female/male/unknown; 396 pretreatment and 251 posttreatment, median 237 days post-surgery) from 7 publicly available repositories in The Cancer Imaging Archive were split into training (536) and test/generalization (111) samples. T1, T1-post-contrast, T2, and FLAIR images were used as inputs into a 3D nnU-Net to predict 3 tumor subregions and resection cavities. We evaluated the performance of networks trained on pretreatment training cases (Pre-Rx network), posttreatment training cases (Post-Rx network), and both pre- and posttreatment cases (Combined networks). Results: Segmentation performance was as good as or better than interrater reliability with median dice scores for main tumor subregions ranging from 0.82 to 0.94 and strong correlations between manually segmented and predicted total lesion volumes (0.94 < R 2 values < 0.98). The Combined network performed similarly to the Pre-Rx network on pretreatment cases and the Post-Rx network on posttreatment cases with fewer false positive resection cavities (7% vs 59%). Conclusions: Neural networks that accurately segment pre- and posttreatment diffuse gliomas have the potential to improve response assessment in clinical trials and reduce provider burden and errors in measurement.
Invariant Delineation of Nuclear Architecture in Glioblastoma Multiforme for Clinical and Molecular Association

Hang Chang,Ju Han,Alexander Borowsky,Leandro Loss,Joe W. Gray,Paul T. Spellman,Bahram Parvin

DOI: https://doi.org/10.1109/tmi.2012.2231420

IF: 10.6

2012-01-01

IEEE Transactions on Medical Imaging

Abstract:Automated analysis of whole mount tissue sections can provide insights into tumor subtypes and the underlying molecular basis of neoplasm. However, since tumor sections are collected from different laboratories, inherent technical and biological variations impede analysis for very large datasets such as The Cancer Genome Atlas (TCGA). Our objective is to characterize tumor histopathology, through the delineation of the nuclear regions, from hematoxylin and eosin (H&E) stained tissue sections. Such a representation can then be mined for intrinsic subtypes across a large dataset for prediction and molecular association. Furthermore, nuclear segmentation is formulated within a multi-reference graph framework with geodesic constraints, which enables computation of multidimensional representations, on a cell-by-cell basis, for functional enrichment and bioinformatics analysis. Here, we present a novel method, multi-reference graph cut (MRGC), for nuclear segmentation that overcomes technical variations associated with sample preparation by incorporating prior knowledge from manually annotated reference images and local image features. The proposed approach has been validated on manually annotated samples and then applied to a dataset of 377 Glioblastoma Multiforme (GBM) whole slide images from 146 patients. For the GBM cohort, multidimensional representation of the nuclear features and their organization have identified 1) statistically significant subtypes based on several morphometric indexes, 2) whether each subtype can be predictive or not, and 3) that the molecular correlates of predictive subtypes are consistent with the literature. Data and intermediaries for a number of tumor types (GBM, low grade glial, and kidney renal clear carcinoma) are available at: http://tcga.lbl.gov for correlation with TCGA molecular data. The website also provides an interface for panning and zooming of whole mount tissue sections with/without overlaid segmentation results for quality control.
An open relaxation-diffusion MRI dataset in neurosurgical studies

Ye Wu,Xiaoming Liu,Yunzhi Huang,Tao Zhou,Fan Zhang

DOI: https://doi.org/10.1038/s41597-024-03013-9

2024-02-08

Scientific Data

Abstract:Diffusion MRI (dMRI) is a safe and noninvasive technique that provides insight into the microarchitecture of brain tissue. Relaxation-diffusion MRI (rdMRI) is an extension of traditional dMRI that captures diffusion imaging data at multiple TEs to detect tissue heterogeneity between relaxation and diffusivity. rdMRI has great potential in neurosurgical research including brain tumor grading and treatment response evaluation. However, the lack of available data has limited the exploration of rdMRI in clinical settings. To address this, we are sharing a high-quality rdMRI dataset from 18 neurosurgical patients with different types of lesions, as well as two healthy individuals as controls. The rdMRI data was acquired using 7 TEs, where at each TE multi-shell dMRI with high spatial and angular resolutions is obtained at each TE. Each rdMRI scan underwent thorough artifact and distortion corrections using a specially designed processing pipeline. The dataset's quality was assessed using standard practices, including quality control and assurance. This resource is a valuable addition to neurosurgical studies, and all data are openly accessible.

multidisciplinary sciences
A Large Open Access Dataset of Brain Metastasis 3D Segmentations with Clinical and Imaging Feature Information

Divya Ramakrishnan,Leon Jekel,Saahil Chadha,Anastasia Janas,Harrison Moy,Nazanin Maleki,Matthew Sala,Manpreet Kaur,Gabriel Cassinelli Petersen,Sara Merkaj,Marc von Reppert,Ujjwal Baid,Spyridon Bakas,Claudia Kirsch,Melissa Davis,Khaled Bousabarah,Wolfgang Holler,MingDe Lin,Malte Westerhoff,Sanjay Aneja,Fatima Memon,Mariam S. Aboian

2023-09-12

Abstract:Resection and whole brain radiotherapy (WBRT) are the standards of care for the treatment of patients with brain metastases (BM) but are often associated with cognitive side effects. Stereotactic radiosurgery (SRS) involves a more targeted treatment approach and has been shown to avoid the side effects associated with WBRT. However, SRS requires precise identification and delineation of BM. While many AI algorithms have been developed for this purpose, their clinical adoption has been limited due to poor model performance in the clinical setting. Major reasons for non-generalizable algorithms are the limitations in the datasets used for training the AI network. The purpose of this study was to create a large, heterogenous, annotated BM dataset for training and validation of AI models to improve generalizability. We present a BM dataset of 200 patients with pretreatment T1, T1 post-contrast, T2, and FLAIR MR images. The dataset includes contrast-enhancing and necrotic 3D segmentations on T1 post-contrast and whole tumor (including peritumoral edema) 3D segmentations on FLAIR. Our dataset contains 975 contrast-enhancing lesions, many of which are sub centimeter, along with clinical and imaging feature information. We used a streamlined approach to database-building leveraging a PACS-integrated segmentation workflow.

Quantitative Methods
Early prognostication of overall survival for pediatric diffuse midline gliomas using MRI radiomics and machine learning: A two-center study

Xinyang Liu,Zhifan Jiang,Holger R Roth,Syed Muhammad Anwar,Erin R Bonner,Aria Mahtabfar,Roger J Packer,Anahita Fathi Kazerooni,Miriam Bornhorst,Marius George Linguraru

DOI: https://doi.org/10.1093/noajnl/vdae108

2024-06-28

Abstract:Background: Diffuse midline gliomas (DMG) are aggressive pediatric brain tumors that are diagnosed and monitored through MRI. We developed an automatic pipeline to segment subregions of DMG and select radiomic features that predict patient overall survival (OS). Methods: We acquired diagnostic and post-radiation therapy (RT) multisequence MRI (T1, T1ce, T2, and T2 FLAIR) and manual segmentations from 2 centers: 53 from 1 center formed the internal cohort and 16 from the other center formed the external cohort. We pretrained a deep learning model on a public adult brain tumor data set (BraTS 2021), and finetuned it to automatically segment tumor core (TC) and whole tumor (WT) volumes. PyRadiomics and sequential feature selection were used for feature extraction and selection based on the segmented volumes. Two machine learning models were trained on our internal cohort to predict patient 12-month survival from diagnosis. One model used only data obtained at diagnosis prior to any therapy (baseline study) and the other used data at both diagnosis and post-RT (post-RT study). Results: Overall survival prediction accuracy was 77% and 81% for the baseline study, and 85% and 78% for the post-RT study, for internal and external cohorts, respectively. Homogeneous WT intensity in baseline T2 FLAIR and larger post-RT TC/WT volume ratio indicate shorter OS. Conclusions: Machine learning analysis of MRI radiomics has potential to accurately and noninvasively predict which pediatric patients with DMG will survive less than 12 months from the time of diagnosis to provide patient stratification and guide therapy.

The University of California San Francisco Adult Longitudinal Post-Treatment Diffuse Glioma MRI Dataset

The University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM) Dataset

The University of California San Francisco Brain Metastases Stereotactic Radiosurgery (UCSF-BMSR) MRI Dataset

The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation

The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics

Supplementary Table from Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array

Treatment-aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction

Nimg-75. Similarity Distances-Based Delta Radiomics (Sddr) Enables Longitudinal Mri Comparisons For Survival Prediction In Gliomas: A Multi-Institutional Validation

Pre- and post-surgery brain tumor multimodal magnetic resonance imaging data optimized for large scale computational modelling

The Rio Hortega University Hospital Glioblastoma dataset: a comprehensive collection of preoperative, early postoperative and recurrence MRI scans (RHUH-GBM)

Glioma Monitoring Via Longitudinal Intracranial Cerebrospinal Fluid Cell-Free DNA.

BIOS-03. REAL WORLD CLINICAL OUTCOMES OF PATIENTS WITH DIFFUSE MIDLINE GLIOMA IN A LONGITUDINAL OUTCOMES REGISTRY

“MASSIVE” brain dataset: Multiple acquisitions for standardization of structural imaging validation and evaluation

ReMIND: The Brain Resection Multimodal Imaging Database

Data from SlicerDMRI: Open Source Diffusion MRI Software for Brain Cancer Research

Segmentation of pre- and posttreatment diffuse glioma tissue subregions including resection cavities

Invariant Delineation of Nuclear Architecture in Glioblastoma Multiforme for Clinical and Molecular Association

An open relaxation-diffusion MRI dataset in neurosurgical studies

A Large Open Access Dataset of Brain Metastasis 3D Segmentations with Clinical and Imaging Feature Information

Early prognostication of overall survival for pediatric diffuse midline gliomas using MRI radiomics and machine learning: A two-center study